The results of a multicenter open observational study of the efficacy and safety of the dietary supplement Neururidine N in patients with acute nonspecific lower back pain in daily outpatient practice (the NEURO-N study)
Authors:
- E.Z. YakupovEYE.Z. Yakupov
- S.G. BurdSBS.G. Burd
- E.R. BarantsevichEBE.R. Barantsevich
- R.A. GamievaRGR.A. Gamieva
- O.I. MendelOMO.I. Mendel
- A.V. LebedevaALA.V. Lebedeva
- Y.V. RublevaYRY.V. Rubleva
- N.V. PantinaNPN.V. Pantina
- T.A. BokitkoTBT.A. Bokitko
- I.I. KovalevaIKI.I. Kovaleva
- M.A. BogomazovaMBM.A. Bogomazova
- A.P. EfimenkoAEA.P. Efimenko
- 23 April 2024
- journal article
- research article
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (11) , 158-164
Abstract
Objective. To study the efficacy and safety of the use of high (200 mg) doses of uridine monophosphate in combination with choline (dietary supplement, dietary supplement, Neururidine N) in the treatment of patients with nonspecific back pain. Material and methods. An open observational study was conducted, which included 101 patients with acute PB; group 1 included 65 patients who received Neurouridine N (1 caps/day) meloxicam (7.5—15 mg/day) and meloxicam (7.5—15 mg/day), 2nd — 36 patients who received only meloxicam (7.5—15 mg/day). The observation period is 30 days. The condition of the patients was assessed on the basis of a visual analog scale (VAS), Roland—Morris questionnaires (ORM) and general clinical impression (CGI). Results. The positive effect of treatment on reducing the severity of pain was noted according to the results of the VAS assessment. In patients of group 1, an earlier improvement in functional status was noted (starting from day 7) according to ORM data (p<0.01), A more pronounced decrease in pain intensity allowed patients of group 1 to stop taking NSAIDs after 14 days (p<0.01). Patients of the 1st group were statistically significantly more satisfied with the results of treatment (CGI questionnaire), the doctors who observed them also regarded the improvement in their condition as more significant compared to the 2nd group. Conclusion. The use of dietary supplement Neururidine N is an effective and safe method of coanalgesic therapy in patients with acute LBP.Keywords
This publication has 10 references indexed in Scilit:
- Pyrimidine nucleotides in pain management. Consensus of the international group of specialistsRussian Journal of Pain, 2023
- Evaluation of the efficacy and safety of the neuroprotective complex Neurouridin in patients with back painS.S. Korsakov Journal of Neurology and Psychiatry, 2021
- The results of a study on the safety of the dietary supplement neurouridine in patients with nonspecific low back pain (MULTINEURO-2)S.S. Korsakov Journal of Neurology and Psychiatry, 2021
- Localised neuropathic pain in the primary care setting: a cross-sectional study of prevalence, clinical characteristics, treatment patterns, quality of life and sleep performanceCurrent Medical Research and Opinion, 2020
- The results of an open observational study on multimodal effects of the efficacy and safety of supplement neurouridine in patients with nonspecific low back pain (MULTINEURO-1)S.S. Korsakov Journal of Neurology and Psychiatry, 2020
- A double-blind, randomized, comparative study of the use of a combination of uridine triphosphate trisodium, cytidine monophosphate disodium, and hydroxocobalamin, versus isolated treatment with hydroxocobalamin, in patients presenting with compressive neuralgiasJournal of Pain Research, 2017
- Burden of Illness Associated with Peripheral and Central Neuropathic Pain among Adults Seeking Treatment in the United States: A Patient-Centered EvaluationPain Medicine, 2014
- Effect of the Combination of Uridine Nucleotides, Folic Acid and Vitamin B12 on the Clinical Expression of Peripheral NeuropathiesPain Management, 2014
- Purinergic signalling: past, present and futureBrazilian Journal of Medical and Biological Research, 2008
- Depletion of substance P from rat primary sensory neurons by ATP, an implication of P2X receptor-mediated release of substance PNeuroscience, 2001